Breaking News Instant updates and real-time market news.

BLUE

Bluebird Bio

$149.90

-6.85 (-4.37%)

, REGN

Regeneron

$394.87

-2.3 (-0.58%)

06:33
08/06/18
08/06
06:33
08/06/18
06:33

Bluebird Bio and Regeneron to collaborate in new cell therapies for cancer

Regeneron Pharmaceuticals (REGN) and bluebird bio (BLUE) announced a collaboration to apply their respective technology platforms to the discovery, development and commercialization of novel immune cell therapies for cancer. The collaborators will specifically leverage Regeneron's VelociSuite platform technologies for the discovery and characterization of fully human antibodies as well as T cell receptorsor TCRs, directed against tumor-specific proteins and peptides, and bluebird bio will contribute its field-leading expertise in gene transfer and cell therapy.

BLUE

Bluebird Bio

$149.90

-6.85 (-4.37%)

REGN

Regeneron

$394.87

-2.3 (-0.58%)

  • 11

    Aug

  • 14

    Aug

  • 20

    Oct

  • 28

    Oct

BLUE Bluebird Bio
$149.90

-6.85 (-4.37%)

08/02/18
PIPR
08/02/18
NO CHANGE
PIPR
Overweight
Piper Jaffray says 'exciting period' ahead for Bluebird Bio
Piper Jaffray analyst Tyler Van Buren said Bluebird Bio made substantial progress in Q2 and reported what he believes were very positive datasets across its key development programs. The analyst, who contends that Bluebird is "entering an exciting period of time," recommends that investors own the shares to realize the additional value that will be generated from LentiGlobin, bb2121(7), and Lenti-D as the company has the potential for its first three product approvals over the period of 2019-2020. Van Buren maintains an Overweight rating on Bluebird Bio shares.
07/30/18
MAXM
07/30/18
NO CHANGE
Target $163
MAXM
Hold
Bluebird Bio price target lowered to $163 from $200 at Maxim
Maxim analyst Jason McCarthy lowered his price target on Bluebird Bio to $163 after the company's announced capital raise, expecting about $630M in proceeds. The analyst also keeps his Hold rating, saying that while the accelerated EMA assessment on LentiGlobin could reduce the review period to 150 days from 210 days, the company has "only incremental catalysts" in the short term.
06/19/18
EVER
06/19/18
UPGRADE
Target $230
EVER
Outperform
Bluebird Bio upgraded to Outperform with $230 price target at Evercore ISI
As previously reported, Evercore ISI analyst Josh Schimmer upgraded Bluebird Bio (BLUE) to Outperform from In Line, stating that its recent updates for LentiGlobin for sickle cell disease and for its myeloma CAR-T program partnered with Celgene (CELG) have increased his view of the prospects for commercial success for both programs. While competitor CAR-T updates may show that bb2121 is not particularly differentiated, it will have a key first-mover advantage and strong commercial partner, Schimmer tells investors. Schimmer raised his price target on Bluebird shares to $230 from $175.
06/19/18
EVER
06/19/18
UPGRADE
EVER
Outperform
Bluebird Bio upgraded to Outperform from In Line at Evercore ISI
REGN Regeneron
$394.87

-2.3 (-0.58%)

08/03/18
BMOC
08/03/18
NO CHANGE
Target $388
BMOC
Market Perform
Regeneron price target raised to $388 from $361 at BMO Capital
BMO Capital analyst Matthew Luchini raised his price target on Regeneron to $388 after its Q2 results showing 'in-line' Eylea sales, a beat from Dupixent, and better than expected earnings coming from lower expenses and taxes. The analyst also attributes the recent improved investor sentiment to a potential weekly SubQ C5 inhibitor, which is expected to start a Phase II trial in 2019. Longer term, the analyst keeps his Market Perform rating on Regeneron given the "concerns about VEGF competitors and key pipeline opportunity uncertainty".
08/03/18
BARD
08/03/18
DOWNGRADE
BARD
Neutral
Regeneron downgraded to Neutral from Outperform at Baird
08/02/18
PIPR
08/02/18
NO CHANGE
Target $450
PIPR
Overweight
Regeneron stock setup 'skewed decidedly to the upside,' says Piper Jaffray
Piper Jaffray analyst Christopher Raymond calls Regeneron Pharmaceuticals' beat in Q2 "impressive." The company is an "emerging operational juggernaut," Raymond tells investors in a post-earnings research note. He believes the stock's setup remains "skewed decidedly to the upside" and keeps an Overweight rating on Regeneron with a $450 price target.
07/19/18
WELS
07/19/18
NO CHANGE
Target $240
WELS
Outperform
Allergan wet AMD data exceed 'unofficial benchmark,' says Wells Fargo
The released efficacy data from Allergan's (AGN) two Phase III trials of its anti-VEGF treatment abicipar in wet age-related macular degeneration looks to have exceeded the "unofficial benchmark set by potential extended-duration competitors," Novartis' (NVS) brolucizumab and Regeneron's (REGN) Eylea, Wells Fargo analyst David Maris tells investors in a research note. The analyst forecasts $125M in sales for abicipar in its first year on the market in 2020 and estimates it will grow to $500M in 2022. Maris keeps an Outperform rating on Allergan with a $240 price target.

TODAY'S FREE FLY STORIES

RHHBY

Roche

$0.00

(0.00%)

05:16
03/19/19
03/19
05:16
03/19/19
05:16
Hot Stocks
Roche announces FDA approval of Tecentriq with chemotherapy for lung cancer »

Roche announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Apr

  • 17

    Apr

  • 19

    Aug

  • 04

    Nov

05:10
03/19/19
03/19
05:10
03/19/19
05:10
General news
FX Action: USD-CAD has remained steady-but-heavy »

FX Action: USD-CAD has…

ALGN

Align Technology

$253.83

1.51 (0.60%)

05:09
03/19/19
03/19
05:09
03/19/19
05:09
Recommendations
Align Technology analyst commentary  »

Align Technology price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGMB

MGM Holdings

$0.00

(0.00%)

, MGM.B

MGM Holdings

$0.00

(0.00%)

05:03
03/19/19
03/19
05:03
03/19/19
05:03
Recommendations
MGM Holdings, MGM Holdings analyst commentary at Imperial Capital »

MGM Holdings price target…

MGMB

MGM Holdings

$0.00

(0.00%)

MGM.B

MGM Holdings

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CWH

Camping World

$13.45

-0.07 (-0.52%)

04:55
03/19/19
03/19
04:55
03/19/19
04:55
Downgrade
Camping World rating change  »

Camping World downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

04:55
03/19/19
03/19
04:55
03/19/19
04:55
Conference/Events
UBS technology analyst to hold an analyst/industry conference call »

Technology Analyst Lowe…

AHT

Ashford Hospitality

$4.81

0.09 (1.91%)

04:55
03/19/19
03/19
04:55
03/19/19
04:55
Conference/Events
Ashford Hospitality management to meet with B. Riley FBR »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

ANDE

Andersons

$34.32

-0.26 (-0.75%)

04:55
03/19/19
03/19
04:55
03/19/19
04:55
Conference/Events
Andersons management to meet with Buckingham »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 07

    May

04:55
03/19/19
03/19
04:55
03/19/19
04:55
General news
Breaking General news story  »

8-Week Bill Announcement…

CPST

Capstone Turbine

$0.93

0.0602 (6.91%)

, CEVA

Ceva

$27.85

-0.63 (-2.21%)

04:55
03/19/19
03/19
04:55
03/19/19
04:55
Conference/Events
Roth Capital to hold a conference »

31st Annual ROTH…

CPST

Capstone Turbine

$0.93

0.0602 (6.91%)

CEVA

Ceva

$27.85

-0.63 (-2.21%)

ORA

Ormat Technologies

$55.25

-0.12 (-0.22%)

ATEA

Astea

$0.00

(0.00%)

AKTS

Akoustis

$6.47

-0.02 (-0.31%)

ALRM

Alarm.com

$61.72

0.74 (1.21%)

VERI

Veritone

$6.49

0.23 (3.67%)

WAAS

AquaVenture

$19.78

-0.6 (-2.94%)

SRAX

Social Reality

$2.65

-0.06 (-2.21%)

MOBL

MobileIron

$5.03

0.03 (0.60%)

RUN

Sunrun

$14.85

0.09 (0.61%)

QTNA

Quantenna Communications

$21.07

-0.21 (-0.99%)

CWCO

Consolidated Water

$13.49

0.09 (0.67%)

EVER

EverQuote

$7.50

0.18 (2.46%)

PXLW

Pixelworks

$4.12

0.33 (8.71%)

BBSI

Barrett Business

$79.51

0.04 (0.05%)

FIVN

Five9

$54.86

0.43 (0.79%)

TMDI

Titan Medical

$3.29

(0.00%)

MNLO

Menlo Therapeutics

$7.98

0.15 (1.92%)

CRWS

Crown Crafts

$5.22

-0.025 (-0.48%)

ASUR

Asure Software

$6.22

-0.03 (-0.48%)

BOXL

Boxlight

$2.85

0.09 (3.26%)

CTEK

CynergisTek

$4.55

0.11 (2.48%)

EIDX

Eidos Therapeutics

$20.22

0.54 (2.74%)

IOTS

Adesto Technologies

$6.33

-0.1 (-1.56%)

SUMR

Summer Infant

$0.75

0.0024 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 20

    Mar

  • 20

    Mar

  • 25

    Mar

  • 25

    Mar

  • 25

    Mar

  • 26

    Mar

  • 28

    Mar

  • 28

    Mar

  • 28

    Mar

  • 21

    May

  • 28

    May

  • 11

    Jun

NOAH

Noah Holdings

$46.87

0.5 (1.08%)

04:55
03/19/19
03/19
04:55
03/19/19
04:55
Conference/Events
Noah Holdings management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

  • 21

    Mar

  • 22

    Mar

ALDR

Alder Biopharmaceuticals

$13.72

0.21 (1.55%)

04:55
03/19/19
03/19
04:55
03/19/19
04:55
Conference/Events
Alder Biopharmaceuticals management to meet with SVB Leerink »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

JMP

JMP Group

$3.86

-0.085 (-2.15%)

04:55
03/19/19
03/19
04:55
03/19/19
04:55
Conference/Events
JMP Group management to meet with Barrington »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

WCN

Waste Connections

$84.90

0.48 (0.57%)

04:55
03/19/19
03/19
04:55
03/19/19
04:55
Conference/Events
Waste Connections management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

  • 17

    May

WIFI

Boingo Wireless

$21.14

-0.65 (-2.98%)

04:55
03/19/19
03/19
04:55
03/19/19
04:55
Conference/Events
Boingo Wireless management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

  • 28

    Mar

  • 29

    Mar

  • 28

    May

MKTX

MarketAxess

$237.77

4.27 (1.83%)

04:55
03/19/19
03/19
04:55
03/19/19
04:55
Conference/Events
MarketAxess management to meet with Buckingham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

MGA

Magna

$49.29

0.45 (0.92%)

04:55
03/19/19
03/19
04:55
03/19/19
04:55
Conference/Events
Magna management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 21

    Mar

CYAD

Celyad

$21.35

(0.00%)

04:55
03/19/19
03/19
04:55
03/19/19
04:55
Conference/Events
Celyad management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

  • 04

    Apr

  • 09

    Apr

AEE

Ameren

$72.49

-0.55 (-0.75%)

04:55
03/19/19
03/19
04:55
03/19/19
04:55
Conference/Events
Ameren management to meet with Wolfe Research »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

NGVT

Ingevity

$106.91

5.72 (5.65%)

04:55
03/19/19
03/19
04:55
03/19/19
04:55
Conference/Events
Ingevity management to meet with Loop Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 25

    Apr

04:55
03/19/19
03/19
04:55
03/19/19
04:55
General news
Breaking General news story  »

4-Week Bill Announcement…

ITCI

Intra-Cellular

$12.84

-0.59 (-4.39%)

04:55
03/19/19
03/19
04:55
03/19/19
04:55
Conference/Events
Intra-Cellular participates in a conference call with JPMorgan »

JPMorgan Biotech Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 27

    Sep

PLYA

Playa Hotels & Resorts

$8.07

0.12 (1.51%)

04:55
03/19/19
03/19
04:55
03/19/19
04:55
Conference/Events
Playa Hotels & Resorts management to meet with SunTrust »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

EXTN

Exterran

$18.30

0.4 (2.23%)

04:55
03/19/19
03/19
04:55
03/19/19
04:55
Conference/Events
Exterran management to meet with Piper Jaffray »

Meetings to be held In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

  • 25

    Apr

ITRM

Iterum Therapeutics

$5.63

0.16 (2.93%)

04:55
03/19/19
03/19
04:55
03/19/19
04:55
Conference/Events
Iterum Therapeutics management to meet with Needham »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.